Focal segmental glomerulosclerosis: Recent advances

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 2, 2008, Pages 138-142

  Pollak, Martin R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Focal segmental glomerulosclerosis; Glomerulus; Nephrotic syndrome; Podocyte

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PODOCIN; PREDNISONE; PUROMYCIN; RAPAMYCIN; SYNAPTOPODIN; TACROLIMUS; WT1 PROTEIN;

CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG PULSE THERAPY; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GENETIC HETEROGENEITY; GEOGRAPHIC DISTRIBUTION; HISTOLOGY; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY FAILURE; NEPHROTIC SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; REMISSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANIMALS; CYTOSKELETON; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEPHROTIC SYNDROME; PODOCYTES; RISK FACTORS; TREATMENT OUTCOME;

EID: 39149128230     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f5dbe4     Document Type: Review

References (68)

1. Franceschini N, North KE, Kopp JB, et al. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: A HuGE review. Genet Med 2006; 8:63-75.
2. Berdeli A, Mir S, Yavascan O, et al. NPHS2 (podicin) mutations in Turkish children with idiopathic nephrotic syndrome. Pediatr Nephrol 2007; 22: 2031-2040.
3. Di Duca M, Oleggini R, Sanna-Cherchi S, et al. Cis and trans regulatory elements in NPHS2 promoter: Implications in proteinuria and progression of renal diseases. Kidney Int 2006; 70:1332-1341.
4. Oleggini R, Bertelli R, Di Donato A, et al. Rare functional variants of podocin (NPHS2) promoter in patients with nephrotic syndrome. Gene Expr 2006; 13:59-66.
5. He N, Zahirieh A, Mei Y, et al. Recessive NPHS2 (podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:31-37.
6. Monteiro EJ, Pereira AC, Pereira AB, et al. NPHS2 mutations in adult patients with primary focal segmental glomerulosclerosis. J Nephrol 2006; 19:366-371.
7. McKenzie LM, Hendrickson SL, Briggs WA, et al. NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 2007; 18:2987-2995.
8. Gbadegesin R, Hinkes B, Vlangos C, et al. Mutational analysis of NPHS and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:509-513.
9. Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: Two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119:e907-e919. This paper clarifies the contribution of mutations in these four genes to the etiology of congenital nephrotic syndrome.
10. Frishberg Y, Feinstein S, Rinat C, et al. The heart of children with steroid-resistant nephrotic syndrome: Is it all podocin? J Am Soc Nephrol 2006; 17:227-231.
11. Huber TB, Schermer B, Muller RU, et al. Podocin and mec-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A 2006; 103:17079-17086. This report demonstrates an interaction between podocin and cholesterol and shows that podocin regulates TRPC6 activity.
12. Huber TB, Schermer B, Benzing T. Podocin organizes ion channel-lipid supercomplexes: Implications for mechanosensation at the slit diaphragm. Nephron Exp Nephrol 2007; 106:e27-e31.
13. Shono A, Tsukaguchi H, Yaoita E, et al. Podocin participates in the assembly of tight junctions between foot processes in nephrotic podocytes. J Am Soc Nephrol 2007; 18:2525-2533.
14. Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722-732.
15. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571-579.
16. Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314-1321.
17. Becker-Cohen R, Bruschi M, Rinat C, et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to antipodocin antibodies. Am J Transplant 2007; 7:256-260.
18. Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38:1397-1405.
19. Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801-1804.
20. Reiser J, Polu KR, Moller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37:739-744.
21. Moller CC, Wei C, Altintas MM, et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007; 18:29-36.
22. Spassova MA, Hewavitharana T, Xu W, et al. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc Natl Acad Sci U S A 2006; 103:16586-16591.
23. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24:251-256.
24. Michaud JL, Chaisson KM, Parks RJ, et al. Fsgs-associated alpha-actinin-4 (k256e) impairs cytoskeletal dynamics in podocytes. Kidney Int 2006; 70:1054-1061.
25. Weins A, Schlondorff JS, Nakamura F, et al. Disease-associated mutant alpha-actinin-4 reveals a mechanism for regulating its F-actin-binding affinity. Proc Natl Acad Sci U S A 2007; 104:16080-16085.
26. Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol 2006; 21:1653-1660.
27. Agarwal AK, Zhou XJ, Hall RK, et al. Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency. J Investig Med 2006; 54:208-213.
28. Huber TB, Kwoh C, Wu H, et al. Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of cd2ap, fyn, and synaptopodin. J Clin Invest 2006; 116:1337-1345.
29. Ghiggeri GM, Dagnino M, Parodi S, et al. Discordant evolution of nephrotic syndrome in mono- and dizygotic twins. Pediatr Nephrol 2006; 21:419-422.
30. Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006; 440:818-823.
31. Verma R, Kovari I, Soofi A, et al. Nephrin ectodomain engagement results in src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 2006; 116:1346-1359. This paper helps to define mechanisms of podocyte cytoskeletal regulation by slit-diaphragm proteins.
32. Garg P, Verma R, Nihalani D, et al. Neph1 cooperates with nephrin to transduce a signal that induces actin polymerization. Mol Cell Biol 2007; 27:8698-8712. This paper helps to define mechanisms of podocyte cytoskeletal regulation by slit-diaphragm protein.
33. Asanuma K, Yanagida-Asanuma E, Faul C, et al. Synaptopodin orchestrates actin organization and cell motility via regulation of rhoa signalling. Nat Cell Biol 2006; 8:485-491.
34. Sever S, Altintas MM, Nankoe SR, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin l is a mechanism for proteinuric kidney disease. J Clin Invest 2007; 117:2095-2104.
35. El-Aouni C, Herbach N, Blattner SM, et al. Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol 2006; 17:1334-1344.
36. Dai C, Stolz DB, Bastacky SI, et al. Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 2006; 17:2164-2175.
37. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004; 44:815-825.
38. Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1:483-487.
39. Parichatikanond P, Chawanasuntorapoj R, Shayakul C, et al. An analysis of 3555 cases of renal biopsy in Thailand. J Med Assoc Thai 2006; 89 (Suppl 2):S106-S111.
40. Alkhunaizi AM. Pattern of renal pathology among renal biopsy specimens in eastern Saudi Arabia. Saudi Med J 2007; 28:1676-1681.
41. D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004; 43:368-382.
42. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2:529-542. This paper proposes refined classifications for pathological classification of FSGS and for the improved classification of human podocyte disorders using etiological and pathological factors.
43. Stokes MB, Valeri AM, Markowitz GS, et al. Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int 2006; 70:1783-1792.
44. Abeyagunawardena AS, Sebire NJ, Risdon RA, et al. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 2007; 22:215-221.
45. Deegens JK, Steenbergen EJ, Borm GF, et al. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population: epidemiology and outcome. Nephrol Dial Transplant 2007.
46. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69:920-926.
47. Chun MJ, Korbet SM, Schwartz MM, et al. Focal segmental glomerulosclerosis in nephrotic adults: Presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:2169-2177.
48. Colquitt JL, Kirby J, Green C, et al. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: A systematic review. Health Technol Assess 2007; 11:iii-iv, ix-xi, 1-93.
49. Abrantes MM, Cardoso LS, Lima EM, et al. Clinical course of 110 children and adolescents with primary focal segmental glomerulosclerosis. Pediatr Nephrol 2006; 21:482-489.
50. Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16:1061-1068.
51. Pei Y, Cattran D, Delmore T, et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional glomerulonephritis registry study. Am J Med 1987; 82:938-944.
52. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7:56-63.
53. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America nephrotic syndrome study group. Kidney Int 1999; 56:2220-2226.
54. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007; 72:1429-1447.
55. Westhoff TH, Schmidt S, Zidek W, et al. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol 2006; 65:393-400.
56. Sinha MD, MacLeod R, Rigby E, et al. Treatment of severe steroid-dependent nephrotic syndrome (sdns) in children with tacrolimus. Nephrol Dial Transplant 2006; 21:1848-1854.
57. Xia Z, Liu G, Gao Y, et al. Fk506 in the treatment of children with nephrotic syndrome of different pathological types. Clin Nephrol 2006; 66:85-88.
58. Bhimma R, Adhikari M, Asharam K, et al. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 2006; 26:544-551.
59. Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006; 1:109-116.
60. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007; 49:310-317.
61. Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:405-411.
62. Mendizabal S, Zamora I, Berbel O, et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20:914-919.
63. Sahin GM, Sahin S, Kantarci G, et al. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton) 2007; 12:285-288.
64. Bhimma R, Adhikari M, Asharam K. Steroid-resistant nephrotic syndrome: The influence of race on cyclophosphamide sensitivity. Pediatr Nephrol 2006; 21:1847-1853.
65. FSGS-CT: A multicenter collaborative study. Pediatr Nephrol 2006; 21:650-749.
66. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive rho signaling. J Am Soc Nephrol 2006; 17:754-764.
67. Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72:455-463.
68. Yang HC, Ma LJ, Ma J, et al. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69:1756-1764.